Quotes

Back To Menu

Zydus Wellness Ltd NSE  /  BSE

FMCG, Small Cap

Invest

22 Oct 2021 | 03:59 PM

2,138.95
-16.25 (-0.75%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts positive since 03-Apr-2020

    Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 03-Apr-2020 at a price of 1216.40.

  • Valuation Rating

    Moderately undervalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.

  • MT Tech Trend

    Trend neutral but previously negative (since 21-Apr-2020)

    The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 21-Apr-2020), the stock traded below its moving average. The confirmed Technical Reverse (Tech Reverse + 1.75%) point is 1381.729.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -9.760.

Risk parameters

  • Risk Zone

    Low

    The stock has been on the low-sensitivity level since 10-Sep-2019.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -117%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 336%.

  • Beta

    40 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 40%.

  • Correlation

    0.33 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.144.45 The medium term value at risk is estimated at 144.45 or 0.10620%

    The value at risk is estimated at 144.45. The risk is therefore 0.10620%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    59.72 Current year to 2021 annualized estimate

    The annualized growth estimate is for the current year to 2021.

  • P/E Ratio

    28.87 Estimated PE for 2021

    The estimated PE is for the year 2021.

  • G/PE Ratio

    2.07 High discount to expected growth due to base effect

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).

  • Dividend Yield

    0% No dividend

    The company is not paying a dividend.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 25-Feb-2020.